Skip to main content
Clinical Trials/NCT04189549
NCT04189549
Unknown
Not Applicable

Preclinical Detection of Sepsis Early in Hospitalized Patients Following Surgery, Injury or Severe Illness (Pre-SEPSIS Trial)

Robert Ehrman5 sites in 1 country2,000 target enrollmentDecember 9, 2019
ConditionsSepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Robert Ehrman
Enrollment
2000
Locations
5
Primary Endpoint
Clinical development of sepsis
Last Updated
6 years ago

Overview

Brief Summary

This clinical study is to evaluate a novel biomarker - CNA Rapid Sepsis Dx - to predict the development of sepsis in patients admitted to the hospital with non-sepsis conditions. Using circulating cell-free DNA (cfDNA) in the blood stream, it has been demonstrated to detect infection response days before clinical evidence of sepsis manifests. The hypothesis is that blood biomarkers drawn daily in the hospital will identify patients who develop sepsis within seven days of hospital presentation.

Detailed Description

This is a prospective observational trial evaluating CNA Rapid Sepsis Dx -novel biomarkers (CNA Diagnostics Inc.; Calgary, Canada) based on circulating cell-free DNA (cfDNA) in the blood stream to identify patients originally admitted with non-sepsis conditions who ultimately develop sepsis according to Sepsis-3 criteria within seven days of hospital presentation. This novel technology has been demonstrated to detect host-related response to infection days before clinical evidence of sepsis manifests. The primary objective of this study is to assess the performance of the novel diagnostic assay, CNA Rapid Sepsis Dx, based on the biomarkers, drawn daily from the day of hospital presentation, to identify patients who ultimately develop sepsis according to Sepsis-3-definition within seven days of hospital presentation. The secondary objective is to correlate the CNA Rapid Sepsis Dx with clinically relevant outcomes such as infections that otherwise do not meet Sepsis-3 criteria, intensive care unit (ICU) length of stay, hospital length of stay, fluid culture results, and hospital mortality.

Registry
clinicaltrials.gov
Start Date
December 9, 2019
End Date
April 30, 2021
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Robert Ehrman
Responsible Party
Sponsor Investigator
Principal Investigator

Robert Ehrman

Assistant Professor of Emergency Medicine

Wayne State University

Eligibility Criteria

Inclusion Criteria

  • Patient 18 years of age or older at the time of enrollment
  • Presence of any of the following high-risk features:
  • Victims of trauma with either an Injury Severity Score of ≥ 15 or a Glasgow Coma Score of ≤ 8\[2\] OR
  • Any patient undergoing high-risk surgical procedures including any emergency surgery and high risk elective surgery procedures involving the thorax, esophagus, stomach, small bowel, large bowel \[3, 4\] OR
  • Any patient being admitted to any ICU setting for any reason with no current evidence or suspicion of active infection (by primary team).\[5, 6\]
  • Able to collect sample within 24 hours of presentation to the hospital.

Exclusion Criteria

  • Prisoners or in police custody
  • Pre-existing infection for which patient is being treated with antibiotics as an outpatient.
  • Plan for ongoing antibiotic therapy by treating team (up to three doses antibiotics for peri-procedure prophylaxis is allowable).
  • Moribund, unlikely to survive the duration of active enrollment
  • Comfort care measures in place or ordered at time of screening OR indication from treating team that active medical care will not be pursued due to patient's condition or patient's/family's wishes.
  • Palliative care or hospice consult at time of screening.

Outcomes

Primary Outcomes

Clinical development of sepsis

Time Frame: Seven Days from hospital presentation

Sepsis determined according to Sepsis-3 definition

Secondary Outcomes

  • SIRS sepsis(Seven Days from hospital presentation)
  • Development of non-Sepsis 3 Infections(Seven Days from hospital presentation)
  • Hospital Length of Stay(Up to 12 months)
  • Body Fluid Culture Results(Seven Days from hospital presentation)
  • Intensive Care Unit Length of Stay(Up to 6 months)

Study Sites (5)

Loading locations...

Similar Trials